炎症与胆固醇对他汀不耐受高危患者心血管事件的预测
而基线LDL-C最高与最低四分位相比,主要复合终点HR为1.19,心血管死亡与全因死亡中性。贝姆多酸在各hsCRP和LDL-C分层中降低心血管事件的疗效相似。
要点
- 他汀不耐受患者中,hsCRP预测心血管事件和死亡强于LDL-C。
- hsCRP升高者风险高,无论LDL-C水平如何。
- 贝姆多酸在各hsCRP和LDL-C分层中疗效相似。
核心结论
- 在他汀不耐受患者中,基线hsCRP预测未来心血管事件和死亡的能力强于LDL-C。
- 贝姆多酸在各hsCRP和LDL-C分层中降低心血管风险的疗效相似。
研究设计与样本
- 随访主要4组分复合终点(心肌梗死、卒中、冠脉血运重建或心血管死亡)及全因死亡。
- 评估基线hsCRP和LDL-C四分位对不良事件的预测,校正传统危险因素和随机治疗分组。
主要发现
- 与安慰剂相比,贝姆多酸6个月时降低hsCRP中位数21.6%,降低LDL-C均值21.1%。
- 基线hsCRP最高 vs 最低四分位:主要心血管复合终点HR 1.43(95%CI 1.24-1.65),心血管死亡HR 2.00(95%CI 1.53-2.61),全因死亡HR 2.21(95%CI 1.79-2.73)。
- 基线LDL-C最高 vs 最低四分位:主要心血管复合终点HR 1.19(95%CI 1.04-1.37),心血管死亡HR 0.90(95%CI 0.70-1.17),全因死亡HR 0.95(95%CI 0.78-1.16)。
- hsCRP升高者风险高,无论LDL-C水平如何。
- 贝姆多酸在各hsCRP和LDL-C水平中降低心血管事件的疗效相似。
临床怎么用
- 对他汀不耐受患者,评估hsCRP有助于识别残余炎症风险高的个体。
- 贝姆多酸可考虑用于他汀不耐受患者,其疗效不受基线hsCRP和LDL-C水平影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein cholesterol (LDLC). Whether these relationships are present among statin-intolerant patients with higher LDLC levels is uncertain but has implications for the choice of preventive therapies, including bempedoic acid, an agent that reduces both LDLC and hsCRP. METHODS: The multinational CLEAR-Outcomes trial (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen Outcomes Trial) randomly allocated 13 970 statin-intolerant patients to 180 mg of oral bempedoic acid daily or matching placebo and followed them for a 4-component composite of incident myocardial infarction, stroke, coronary revascularization, or cardiovascular death, and for all-cause mortality. Quartiles of increasing baseline hsCRP and LDLC were assessed as predictors of future adverse events after adjustment for traditional risk factors and randomized treatment assignment. RESULTS: Compared with placebo, bempedoic acid reduced median hsCRP by 21.6% and mean LDLC levels by 21.1% at 6 months. Baseline hsCRP was significantly associated with the primary composite end point of major cardiovascular events (highest versus lowest hsCRP quartile; hazard ratio [HR], 1.43 [95% CI, 1.24-1.65]), cardiovascular mortality (HR, 2.00 [95% CI, 1.53-2.61]), and all-cause mortality (HR, 2.21 [95% CI, 1.79-2.73]). By contrast, the relationship of baseline LDLC quartile (highest versus lowest) to future events was smaller in magnitude for the primary composite cardiovascular end point (HR, 1.19 [95% CI, 1.04-1.37]) and neutral for cardiovascular mortality (HR, 0.90 [95% CI, 0.70-1.17]) and all-cause mortality (HR, 0.95 [95% CI, 0.78-1.16]). Risks were high for those with elevated hsCRP irrespective of LDLC level. Bempedoic acid demonstrated similar efficacy in reducing cardiovascular events across all levels of hsCRP and LDLC. CONCLUSIONS: Among contemporary statin-intolerant patients, inflammation assessed by hsCRP predicted risk for future cardiovascular events and death more strongly than hyperlipidemia assessed by LDLC. Compared with placebo, bempedoic acid had similar efficacy for reducing cardiovascular risk across hsCRP and LDLC strata. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02993406.
引用
- Ridker PM, Lei L, Louie MJ, et al. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance. Circulation. 2023. PMID: 37929602. doi:10.1161/CIRCULATIONAHA.123.066213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。